News & Events
AbbVie and Anima Biotech Announce Collaboration for the Discovery and Development of mRNA Biology Modulators against Oncology and Immunology Targets
When: Jan. 10th, 2023
AbbVie (NYSE: ABBV), and Anima Biotech (Anima), today announced a collaboration to discover and develop mRNA biology modulators for three targets across Oncology and Immunology. Anima will use its mRNA Lightning platform to discover novel mRNA biology modulators against the collaboration targets providing AbbVie exclusive rights to license and further develop and commercialize the programs.
“This collaboration will give AbbVie access to Anima’s leading technology platform and deep expertise in mRNA biology and will help further strengthen AbbVie’s world class capabilities in discovering and developing drugs to make a difference in patient’s lives,” said Jonathon Sedgwick, Ph.D., vice president and global head of discovery research, AbbVie. “Modulating mRNA biology with small molecules is a new approach and has the potential to address ‘undruggable’ targets with implications across multiple therapy areas.”
”Anima’s differentiated approach in the field of small molecule mRNA drugs combines phenotypic screening with AI-driven elucidation of the mechanisms of action. The power of our mRNA Lightning platform is validated by our multiple partnerships and a growing internal pipeline,” said Yochi Slonim, co-founder and chief executive officer, Anima. “We are excited to partner with AbbVie, a recognized global leader in Oncology and Immunology, and are looking forward to start working with their excellent scientific team in a close collaboration.”
Under the terms of the agreement, Anima will receive an upfront payment of $42 million and may be eligible to receive up to $540 million in option fees and research and development milestones in the aggregate across the three targets, with potential for further commercial milestones as well as tiered royalties on net sales. AbbVie has an option to expand the collaboration with up to three additional targets under the same terms as the initial collaboration, which may increase the potential value of the collaboration.
Biotech Showcase 2023
When: Jan. 10th, 2023 to Jan. 11th, 2023
Where: San Francisco, CA
Anima Biotech will be attending this year’s Biotech Showcase and is looking forward to connecting with other industry experts. Our chief business officer, Kevin Pong, Ph.D., will give a corporate presentation on Jan. 9th at 9:45 A.M. PST highlighting our unique approach to the discovery of small molecule mRNA drugs.
5th RNA Targeting Drug Development Summit
When: Dec. 13th, 2022 to Dec. 15th, 2022
Where: Boston, MA
Anima Biotech has been invited to participate in a panel discussion and presentation at the 5th RNA Targeting Drug Development Summit. Our chief business officer, Kevin Pong, Ph.D., will participate in the Biopharma & Investment Partnerships panel – Exploring the Future of RNA Investment & Collaborations Space for Small Molecule on Dec. 14th at 11:50 A.M. Additionally, he will give a talk titled, “mRNA Lightning Platform-Discovery of Small Molecule mRNA Drugs and their Mechanisms of Action” on Dec. 15th at 11:45 A.M. Dr. Pong will highlight our mRNA Lightning platform and how our unique AI driven MOA elucidation and phenotypic screening-based approach has elucidated novel targets that affect mRNA biology.
4th NovAliX Virtual Conference
When: Nov. 17th, 2022
Anima Biotech has been invited to participate in a short session at the 4th NovAliX Virtual Conference. Our co-founder and chief scientific officer, Iris Alroy, Ph.D., will present a short talk titled “Discovery of Small Molecule mRNA Drugs and their Mechanisms of Action using Phenotypic Screening with AI-driven MOA Elucidation” taking place from 11:00 AM to 1:00 PM ET. The talk highlights our mRNA Lightning platform and how our unique AI and phenotypic screening-based approach has elucidated novel targets that affect mRNA biology, driving our lead programs in fibrosis and oncology with demonstrated efficacy in animal and patient-derived models.
4th Annual Targeting RNA
When: Oct. 18th, 2022 to Oct. 19th, 2022
Where: Boston, MA
Anima Biotech has been invited to participate at the 4th Annual Targeting RNA conference hosted by Cambridge Healthtech Institute. Kevin Pong, Ph.D., Anima’s Chief Business Officer, will give a presentation titled, “Discovery of Small Molecule mRNA Drugs and Their Mechanisms of Action Using Phenotypic Screening with AI-Driven MOA Elucidation” taking place on October 18th at 10:25 a.m. ET.
IPF Summit 2022
When: Aug. 29th, 2022 to Sep. 1st, 2022
Where: Boston, MA
Anima Biotech has been invited to participate in the IPF Summit 2022 hosted by Hanson Wade.
Moty Klepfish, Ph.D., Anima’s Principal Scientist, Fibrosis will give a presentation titled, “Discussing Collagen Type I mRNA Translation Inhibition in Idiopathic Pulmonary Fibrosis,” taking place on August 30th at 2:30 p.m. ET.
The IPF Summit is the largest gathering of IPF experts spanning four days of topics such as rethinking senescence to effectively repairing and regenerating lung tissue, to leveraging synthetic control arms in placebo-controlled trials.
Anima Biotech achieves milestone in Takeda collaboration
When: Jul. 20th, 2022
Anima Biotech announced that the company has achieved a milestone in its collaboration with Takeda.
The milestone relates to one of the two newly initiated programs as part of the multi-target collaboration. This achievement entitles Anima to an undisclosed milestone payment.
Anima Biotech and Takeda entered in the collaboration in March 2021 to discover and develop a new class of medicines for genetically-defined neurological diseases. Under the terms of the agreement, Anima Biotech used its mRNA Lightning platform to discover novel mRNA translation modulators against the collaboration targets. The collaboration also includes Anima’s Huntington’s Disease program against the HTT mutated protein.
Oxford Global Discovery Europe
When: Jun. 9th, 2022 to Jun. 10th, 2022
Where: Berlin, Germany
Anima Biotech has been invited to participate in the Oxford Global Discovery Europe Summit.
Our Co-Founder and Chief Scientific Officer, Iris Alroy, Ph.D., will participate in a panel discussion titled, “Targeting The RNA As a Modality,” on June 9, 2022, at 2:10 p.m. CEST.
Anima’s Technology Lead, Yoni Sheinberger, Ph.D., will also give a presentation titled, “Unlocking mRNA biology target space by combining biology with AI/ML mRNA image analysis,” taking place on June 9th at 5:15 p.m. CEST.
The Oxford Global Discovery Europe Summit will bring together leading experts in the fields of Organoid Discovery, Phenotypic Screening, Targeted Protein Degradation, AI Computational Drug Design and Lead Optimization.
Cambridge Healthtech Institute’s 3rd Annual RNA-Targeting Small Molecule Drugs
When: Apr. 20th, 2022 to Apr. 21st, 2022
Where: San Diego, CA & online
Anima Biotech’s Co-Founder and Chief Scientific Officer, Iris Alroy, Ph.D. will provide a presentation, titled, “mRNA Lightning Platform: A novel Platform for the Discovery of Small Molecule mRNA Drugs,” at the 3rd Annual RNA-Targeting Small Molecule Drugs: Novel Approaches to Modulate RNA Binding, Interactions and Function being held virtually and in San Diego, CA on April 21, 2022, at 2:10 PM PT. The conference on RNA-Targeting Small Molecule Drugs will highlight some of the innovative approaches being pursued to find new small molecule drugs for modulating RNA for therapeutic intervention.
Drug Discovery Webinar 2022
When: Mar. 28th, 2022 to Mar. 30th, 2022
Our Co-Founder and Chief Scientific Officer, Iris Alroy, Ph.D. has been invited to present, “mRNA translation monitoring as a new strategy in drug discovery,” during the Scholars International Webinar on Advances in Drug Discovery and Development on March 29th, 11:35-12:10 GMT. The Drug Discovery Webinar 2022 aims to bring together renowned researchers, scientists and scholars to exchange and share their experiences on all aspects of chemistry, drug discovery, and drug design with a focus on the latest advancements in the drug discovery and development process.